The National Times - Neglected killer: kala-azar disease surges in Kenya

Neglected killer: kala-azar disease surges in Kenya


Neglected killer: kala-azar disease surges in Kenya
Neglected killer: kala-azar disease surges in Kenya / Photo: © AFP

For nearly a year, repeated misdiagnoses of the deadly kala-azar disease left 60-year-old Harada Hussein Abdirahman's health deteriorating, as an outbreak in Kenya's arid regions claimed a record number of lives.

Change text size:

Kala-azar is spread by sandflies and is one of the most dangerous neglected tropical diseases, with a fatality rate of 95 percent if untreated, causing fever, weight loss, and enlargement of the spleen and liver.

Cases of kala-azar, also known as visceral leishmaniasis, have spiked in Kenya, from 1,575 in 2024 to 3,577 in 2025, according to the health ministry.

It is spreading to previously untouched regions and becoming endemic, driven by changing climatic conditions and expanding human settlements, say health officials, with millions potentially at risk of infection.

Abdirahman, a 60-year-old grandmother, was bitten while herding livestock in Mandera county in Kenya's northeast, a hotspot for the parasite but with only three treatment facilities capable of treating the disease.

She was forced to rely on a local pharmacist who repeatedly misdiagnosed her with malaria and dengue fever for about a year.

"I thought I was dying," she told AFP. "It is worse than all the diseases they thought I had."

She was left with hearing problems after the harsh treatment to remove the toxins from her body.

East Africa generally accounts for more than two-thirds of global cases, according to the World Health Organization.

"Climate change is expanding the range of sandflies and increasing the risk of outbreaks in new areas," said Dr Cherinet Adera, a researcher at the Drugs for Neglected Diseases Initiative in Nairobi.

- 'So scared' -

A surge in cases among migrant workers at a quarry site in Mandera last year led authorities to restrict movement at dusk and dawn when sandflies are most active.

At least two workers died, their colleagues said. Others returned to their villages and their fates are unknown.

"We did not know about the strange disease causing our colleagues to die," said Evans Omondi, 34, who travelled hundreds of miles from western Kenya to work at the quarry.

"We were so scared," added Peter Otieno, another worker from western Kenya, recalling how they watched their infected colleagues waste away day by day.

In 2023, the six most-affected African nations adopted a framework in Nairobi to eliminate the disease by 2030.

But there are "very few facilities in the country able to actively diagnose and treat," kala-azar, Dr Paul Kibati, tropical disease expert for health NGO Amref, told AFP.

He said more training is needed as mistakes in testing and treatment can be fatal.

The treatment can last up to 30 days and involves daily injections and often blood transfusions, costing as much as 100,000 Kenyan shillings ($775), excluding the cost of drugs, said Kibati, adding there is a need for "facilities to be adequately equipped".

The sandfly commonly shelters in cracks in poorly plastered mud houses, anthills and soil fissures, multiplying during the rainy season after prolonged drought.

Northeastern Kenya, as well as neighbouring regions in Ethiopia and Somalia, have experienced a devastating drought in recent months.

"Kala-azar affects mostly the poorest in our community," Kibati said, exacerbated by malnutrition and weak immunity.

"We are expecting more cases when the rains start," Kibati said.

F.Hammond--TNT

Featured

Nearly 1,100 flights cancelled after UK air traffic control glitch

Almost 1,100 flights to and from UK airports were cancelled Tuesday due to what the country's air traffic control service called a technical issue, in the latest glitch to spark travel chaos.

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Change text size: